Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $215M
Investors 2
| Date | Name | Website |
| 16.04.2022 | Jeito Capi... | jeito.life |
| - | Alpha Wave... | alphawaveg... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.01.2024 | Series B | $95M | - |
| 01.11.2022 | Series A | $120M | - |
Mentions in press and media 7
| Date | Title | Description |
| 05.01.2024 | Fierce Biotech Fundraising Tracker '24: Lykos lands $100M; HI-Bio secures $95M | A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's tracker, including any fundraising rounds north ... |
| 04.01.2024 | HI-Bio Completes $95M Series B Round | SOUTH SAN FRANCISCO, CA, HI-Bio today announced the closing of a $95 million Series B financing round. >> Click here for more funding data on Human Immunology Biosciences >> To export Human Immunology Biosciences funding dat... |
| 04.01.2024 | HI-Bio Raises $95M in Series B Funding | Human Immunology Biosciences (HI-Bio), a San Francisco, CA-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), raised $95M in Series B funding. The round was led... |
| 01.11.2022 | Arch-backed HI-Bio launches with 2 clinical-stage therapies from MorphoSys and $120M in cash | Oftentimes, a newly launched biotech’s first task is to pour initial financing into the preclinical development of their starting assets. HI-Bio—short for Human Immunology Biosciences—has elected to chart a different course, emerging from s... |
| 01.11.2022 | Human Immunology Biosciences Raises $120M in Funding | Human Immunology Biosciences (HI-Bio™), a South San Francisco, CA-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), launched with $120m in financing. The compa... |
| 01.11.2022 | HI-Bio Launches With $120M | SOUTH SAN FRANCISCO, CA, Human Immunology Biosciences announced its launch with $120 million in financing. >> Click here for more funding data on Human Immunology Biosciences >> To export Human Immunology Biosciences funding... |
| - | Human Immunology Biosciences | “HI-Bio leverages human genetic and immunological insights to deliver targeted, effective medicines to patients with immune-mediated diseases.” |